08.02.13
Thermo Fisher Scientific Inc. is opening a new manufacturing plant in Singapore to produce dry powder media (DPM), an important cell culture raw material used to manufacture biologics, including vaccines and anticancer therapeutics. The facility is the first cell culture DPM production site in Singapore and is designed to meet the increased global requirements from biopharmaceutical companies to mitigate critical raw material supply risks.
The 30,800 sq.-ft. facility will provide manufacturing redundancy of DPM to help ensure an uninterrupted supply to global biopharmaceutical customers. The facility will also serve as an additional logistics hub for DPM distribution to Asia Pacific customers. The new facility is cGMP-compliant and the equipment used is in compliance with 21 CFR 820, ISO 9001:2000, and ISO 13485:200 guidelines.
“Asia continues to be our fastest-growing market and a central contributor to our growth,” said Greg Herrema, president of Biosciences at Thermo Fisher Scientific. “Our new Singapore facility further strengthens our global presence, expands our manufacturing infrastructure and establishes local production capabilities to meet increased demand for biologic drug discovery and development in Asia.”
The 30,800 sq.-ft. facility will provide manufacturing redundancy of DPM to help ensure an uninterrupted supply to global biopharmaceutical customers. The facility will also serve as an additional logistics hub for DPM distribution to Asia Pacific customers. The new facility is cGMP-compliant and the equipment used is in compliance with 21 CFR 820, ISO 9001:2000, and ISO 13485:200 guidelines.
“Asia continues to be our fastest-growing market and a central contributor to our growth,” said Greg Herrema, president of Biosciences at Thermo Fisher Scientific. “Our new Singapore facility further strengthens our global presence, expands our manufacturing infrastructure and establishes local production capabilities to meet increased demand for biologic drug discovery and development in Asia.”